Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis

Journal of Neuroimmunology

Volumn 195, Issue 1-2, 2008, Pages 108-115

  Furukawa, Yutaka ^a   Yoshikawa, Hiroaki ^a   Iwasa, Kazuo ^a   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cytokine; Immunotherapy; Myasthenia gravis; Tacrolimus

Indexed keywords

ANTIBIOTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PREDNISOLONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL CULTURE; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CREATININE CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERKALEMIA; IMMUNOMODULATION; LONG TERM CARE; LYMPHOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; MYASTHENIA GRAVIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PYELONEPHRITIS; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; SIDE EFFECT; THYMECTOMY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PREDNISOLONE; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TACROLIMUS; TIME FACTORS;

EID: 41949099206     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.12.008     Document Type: Article

References (33)

1. Bonifati D.M., and Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J. Neurol. 244 (1997) 542-547
2. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116 (2006) 2843-2854
3. De Feo L.G., Schottlender J., Martelli N.A., and Molfino N.A. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 26 (2002) 31-36
4. de Jager W., te Velthuis H., Prakken B.J., Kuis W., and Rijkers G.T. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin. Diagn. Lab. Immunol. 10 (2003) 133-139
5. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., and de Vries J.E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174 (1991) 915-924
6. Evoli A., Di Schino C., Marsili F., and Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 25 (2002) 111-114
7. Fiorentino D.F., Bond M.W., and Mosmann T.R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170 (1989) 2081-2095
8. Flanagan W.M., Corthesy B., Bram R.J., and Crabtree G.R. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 352 (1991) 803-807
9. Fujii Y., and Lindstrom J. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis. J. Immunol. 141 (1988) 3361-3369
10. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., and Roncarolo M.G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997) 737-742
11. Harding M.W., Galat A., Uehling D.E., and Schreiber S.L. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 341 (1989) 758-760
12. Hoeve M.A., Savage N.D., de Boer T., Langenberg D.M., de Waal Malefyt R., Ottenhoff T.H., and Verreck F.A. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur. J. Immunol. 36 (2006) 661-670
13. Jaretzki III A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S., and Sanders D.B. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55 (2000) 16-23
14. Kellar K.L., Kalwar R.R., Dubois K.A., Crouse D., Chafin W.D., and Kane B.E. Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants. Cytometry 45 (2001) 27-36
15. Khanna A., Cairns V., and Hosenpud J.D. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation 67 (1999) 614-619
16. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., and Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (Tokyo) 40 (1987) 1249-1255
17. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo) 40 (1987) 1256-1265
18. Konishi T., Yoshiyama Y., Takamori M., and Saida T. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J. Neurol. Neurosurg. Psychiatry 76 (2005) 448-450
19. Liu J., Farmer Jr. J.D., Lane W.S., Friedman J., Weissman I., and Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66 (1991) 807-815
20. Nagane Y., Utsugisawa K., Obara D., Kondoh R., and Terayama Y. Efficacy of low-dose FK506 in the treatment of myasthenia gravis-a randomized pilot study. Eur. Neurol. 53 (2005) 146-150
21. Palace J., Newsom-Davis J., and Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50 (1998) 1778-1783
22. Pascuzzi R.M., Coslett H.B., and Johns T.R. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann. Neurol. 15 (1984) 291-298
23. Phillips II L.H., and Torner J.C. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 47 (1996) 1233-1238
24. Ponseti J.M., Azem J., Fort J.M., Lopez-Cano M., Vilallonga R., Buera M., Cervera C., and Armengol M. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 64 (2005) 1641-1643
25. Roncarolo M.G., and Levings M.K. The role of different subsets of T regulatory cells in controlling autoimmunity. Curr. Opin. Immunol. 12 (2000) 676-683
26. Rostedt A., Padua L., and Stalberg E.V. Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur. J. Neurol. 13 (2006) 191-193
27. Sugiyama M., Funauchi M., Yamagata T., Nozaki Y., Yoo B.S., Ikoma S., Kinoshita K., and Kanamaru A. Predominant inhibition of Th1 cytokines in New Zealand black/white F1 mice treated with FK506. Scand. J. Rheumatol. 33 (2004) 108-114
28. Tocci M.J., Matkovich D.A., Collier K.A., Kwok P., Dumont F., Lin S., Degudicibus S., Siekierka J.J., Chin J., and Hutchinson N.I. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. 143 (1989) 718-726
29. Undre N.A., Stevenson P., and Schafer A. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant. Proc. 31 (1999) 21S-24S
30. Wolfe G.I., Herbelin L., Nations S.P., Foster B., Bryan W.W., and Barohn R.J. Myasthenia gravis activities of daily living profile. Neurology 52 (1999) 1487-1489
31. Yoshikawa H., Mabuchi K., Yasukawa Y., Takamori M., and Yamada M. Low-dose tacrolimus for intractable myasthenia gravis. J. Clin. Neurosci. 9 (2002) 627-628
32. Yoshikawa H., Satoh K., Yasukawa Y., and Yamada M. Cytokine secretion by peripheral blood mononuclear cells in myasthenia gravis. J. Clin. Neurosci. 9 (2002) 133-136
33. Zhang G.X., Navikas V., and Link H. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve 20 (1997) 543-551